Tissue culture based in-vitro experimental modeling of human inherited disorders provides insight into the cellular and molecular mechanisms involved and the underlying genetic component influencing the disease phenotype. The breakthrough development of induced pluripotent stem cell (iPSC) technology represents a quantum leap in experimental modeling of human diseases, providing investigators with a self-renewing and thus unlimited source of pluripotent cells for targeted differentiation into functionally relevant disease specific tissue/cell types. The existing rich bio-resource of Epstein-Barr virus (EBV) immortalized lymphoblastoid cell line (LCL) repositories generated from a wide array of patients in genetic and epidemiological studies worldwide, many of them with extensive genotypic, genomic and phenotypic data already existing, provides a great opportunity to reprogram iPSCs from any of these LCL donors in the context of their own genetic identity for disease modeling and disease gene identification. However, due to the low reprogramming efficiency and poor success rate of LCL to iPSC reprogramming, these LCL resources remain severely underused for this purpose. Here, we detailed step-by-step instructions to perform our highly efficient LCL-to-iPSC reprogramming protocol using EBNA1/OriP episomal plasmids encoding pluripotency transcription factors (i.e., OCT3/4, SOX2, KLF4, L-MYC, and LIN28), mouse p53DD (p53 carboxy-terminal dominant-negative fragment) and commercially available reprogramming media. We achieved a consistently high reprogramming efficiency and 100% success rate (> 200 reprogrammed iPSC lines) using this protocol.
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Protocol This changed dramatically in 2006 when Takahashi and Yamanaka made the seminal discovery that mouse skin fibroblasts, using a simple cocktail of pluripotency transcription factors, can be reprogrammed into an induced pluripotent stem cell (iPSC) state that shares the indefinite self-renewal and pluripotent differentiation capacities of ESCs [5] . One year later, the same investigators, as well as groups headed by James Thomson and George Daley, succeeded in converting human fibroblasts into iPSCs [6] [7] [8] .
Reprogramming to pluripotency has now been demonstrated starting with a variety of somatic cell types, including immortal cell lines such as LCLs [9] [10] [11] [12] [13] . However, due to the low reprogramming efficiency and poor success rate of the other cell types including LCLs, dermal fibroblasts isolated from skin biopsies remains the material of choice for reprogramming experiments. Therefore, the already existing rich bio-resource of numerous LCL repositories generated from a wide array of patients, many of them with extensive genotypic and phenotypic data already generated, remains severely underused for this purpose.
We developed and published a highly efficient iPSC reprogramming methodology for cryopreserved LCLs [14] . The two major changes we made in the cocktail of reprogramming factors (i.e., the use of a mouse p53 carboxy-terminal dominant-negative fragment for cellular TP53 suppression and the removing of SV40LT from our reprogramming factors cocktail) has significantly improved the efficiency and success rate of LCL to iPSC reprogramming compared to the previously published methods [12, 13, 15] . Using our efficient iPSC reprogramming methodology, we have achieved 100% success rate in reprogramming cryopreserved LCLs of more than 200 individuals of our San Antonio Family Heart Study cohort for disease modeling and disease gene identification approaches. We strongly believe that a step-by-step protocol of our methodology will be beneficial to many laboratories worldwide intending to utilize cryopreserved LCLs for iPSC generation. Furthermore, the majority of the media and other materials used in this protocol are available from commercial or public sources and requires minimal to no further re-optimization, making this protocol easily reproducible by other laboratories.
The differential gene expression analysis of the cellular and EBV viral genes, as well as the quantitative PCR analysis of the EBV DNA in the LCL reprogrammed iPSCs, shows that transcription and replication of the EBV genome are inhibited in the reprogrammed iPSCs, which ultimately results in the complete depletion of the EBV genome from the reprogrammed iPSCs [12] [13] [14] [15] , making the iPSCs and iPSC differentiated disease target cells much more suitable for disease modeling than the original LCLs.
MATERIALS

Reagents, media and solutions
Equipment 9 Countess Automated Cell Counter (Thermo Fisher Scientific) 9 4D-Nucleofector System (Lonza) 9 Plate Vortexer (Electron Microscopy Sciences) 9 Mr. Frosty Cryo 1°C freezing container (Nalgene, Thermo Fisher Scientific, USA) 9 Inverted Microscope (Zeiss or any equivalent) 9 Centrifuge (Eppendorf or any equivalent) 9 CO 2 Cell culture Incubator (Panasonic or any equivalent) 9 Magnetic hot plate stirrer (Any make) 9 Pipet-Aid Pipette Controller (Drummond or any equivalent) 9 Variable volume pipette set 0.5 µl to 1000 µl (Eppendorf or any equivalent)
PROCEDURE
For iPSC reprogramming of cryopreserved LCLs, the LCLs are propagated and while still in logarithmic growth phase, nucleofected with episomal plasmids (pCEhOCT3/4, pCE-hSK, pCE-hUL, and pCE-mp53DD), encoding reprogramming factors (i.e., OCT3/4, SOX2, KLF4, LMYC, and LIN28), and a mouse p53 carboxy-terminal dominant-negative fragment using 4D-Nucleofector X Kit and 4D-Nucleofector system. The plasmids are described in Okita et al. [11] and can be obtained from the Addgene plasmid repository. The Institutional Review Board of the University of Texas Rio Grande Valley has approved all methods described here.
Lymphoblastoid cell culture 1. Culturing cryopreserved lymphoblastoid cell line(s)
1.1.
Warm phosphate buffered saline (PBS) without CaCl 2 and MgCl 2 and RPMI complete medium to 37°C before starting the protocol to ensure that the thawing procedure is done as quickly as possible.
1.2.
Label a T-25 cell culture flask, add 5 ml of RPMI complete medium and incubate in a CO 2 incubator at 37°C, 5% CO 2 and atmospheric O 2 .
1.3.
Quickly thaw a vial of cryopreserved cells in a 37°C water bath by gently shaking the cryovial continuously until only a small frozen cell pellet remains.
1.4.
Remove the cryovial from the water bath and wipe it with 70% ethanol or isopropanol.
1.5.
Transfer cells (~1 ml) from the cryovial to a pre-labeled 15 ml tube and add 9 ml of pre-warmed (37°C) PBS without CaCl 2 and MgCl 2 with gentle mixing.
1.6. Centrifuge cells at 500 × g for 5 min at room temperature.
1.7.
Aspirate supernatant, leaving the cell pellet intact. Gently re-suspend the cell pellet in 2 ml of prewarmed RPMI complete medium by pipetting 2-3 times using a 5 ml pipette.
1.8.
Transfer the cells to the T-25 cell culture flask prepared in step 1.2 and incubate in a CO 2 incubator at 37°C, 5% CO 2 and atmospheric O 2 .
1.9.
Culture cells for 5-7 d or until the desired number of cells are achieved, changing medium every 2-3 d.
TIP:
In general, one frozen vial containing 3-5 × 10 6 cells can be successfully thawed into one T-25 cell culture flask in 5-7 ml of medium. However, medium volume and culture vessel may need to be optimized as per the cell numbers.
iPSC reprogramming 2. Pre-nucleofection POL Scientific Protocol 2.1. Inspect cell culture microscopically for any sign of infection. A mycoplasma test is optional but recommended.
2.2.
To keep the cell in logarithmic growth phase, passage LCL culture 24 h before nucleofection at a density of about 0.2 to 0.5 × 10 6 cells/ml.
NOTE:
To obtain optimal nucleofection efficiency cells must be in logarithmic growth phase. The plasmid DNA should be highly purified, preferably by using endotoxin-free kits; A260:A280 ratio should be at least 1.8.
Nucleofection
Nucleofection is performed using SE Cell Line 4D-Nucleofector X Kit and 4D-Nucleofector DN-100 program on a 4D-Nucleofector system. 3.1. Label a 35 mm cell culture dish and add 1.4 ml RPMI complete medium. Incubate the dish in a CO 2 incubator at 37°C, 5% CO 2 and atmospheric O 2 .
3.2.
Warm PBS without CaCl 2 and MgCl 2 and RPMI complete medium to 37°C. 
3.5.
Thaw plasmid DNA on ice and prepare plasmid mix by adding equal amounts of pCEh-OCT3/4, pCE-hSK, pCE-hUL, and pCE-mp53DD plasmid DNA (250 ng each/sample) in a 0.5 ml tube. Keep the tube on ice.
3.6.
To prepare LCLs for nucleofection, gently pipette LCL culture 3-5 times to make single cell suspension, then collect 5 ml of cell suspension in a 15 ml tube and centrifuge at 500 × g for 5 min at room temperature.
3.7.
Aspirate the supernatant and resuspend cells in 3-5 ml of pre-warmed PBS without CaCl 2 and MgCl 2 .
3.8.
Determine the cell density using preferred cell-counting method and aliquot 4 × 10 5 cells in a 1.5 ml microcentrifuge tube.
3.9.
Centrifuge the LCL aliquot at 500 × g for 5 min at room temperature. Remove supernatant completely.
3.10
. Add 1 μg of the plasmid DNA mix prepared in step 3.5 and resuspend the cell pellet gently in 20 μl of room temperature nucleofector solution mix prepared in step 3.4.
NOTE:
The volume of plasmid DNA mix should not exceed 10% of the total nucleofection reaction volume.
3.11.
Transfer 20 μl of the cells and plasmid DNA mix into a well of 16-well nucleocuvette strip (supplied with nucleofection kit).
3.12.
Gently tap the nucleocuvette strip to make sure the sample covers the bottom of the cuvette.
3.13.
Place nucleocuvette strip into the retainer of the 4D-Nucleofector X Unit and start nucleofection.
3.14.
After run completion, remove the nucleocuvette strip from the retainer, add 80 μl of pre-warmed (37°C) RPMI complete medium, and incubate for 5 min at room temperature.
3.15.
Mix cells by gently pipetting 2-3 times and transfer to the 35 mm cell culture dish prepared in step 3.1.
3.16.
Transfer the culture dish to a CO 2 incubator at 37°C, 5% CO 2 and atmospheric O 2 and allow the cells to recover overnight (16-18 h).
NOTE:
Leaving cells in nucleofector solution for extended periods of time may lead to reduced transfection efficiency and cell viability. CAUTION: Take all precautions; do not discard cells during the medium change up to this stage. Use a pipette to remove spent medium rather than an aspirator.
TIP: By days 7-9, cells will start to adhere to the well surface and changes in cellular morphology can be observed ( Fig. 1) .
4.4.
On day 11, replace spent medium with 2 ml of pre-warmed (37°C) TeSR-E7 medium.
TIP:
The cells that are still in suspension (not adhered to the well surface) can be discarded from this stage onwards.
4.5.
Day 13 to 14 when iPSC like cell colonies start to appear ( Fig. 1) , transition the culture to human pluripotent stem cell maintenance medium (mTeSR-1) by replacing spent medium with fresh 1 ml mTeSR-1 medium.
4.6.
From day 15 onwards, change spent medium with 2 ml of pre-warmed (37°C) mTeSR-1 medium daily.
NOTE:
From day 15 onward, an aspirator may be used to remove spent media.
4.7.
On days 18-21, 10 to 15 colonies morphologically similar to human ESCs ( Fig. 1 and Fig. 2A ) are manually picked for further expansion. Refer to following section for detailed protocol.
NOTE:
The number of reprogrammed iPSC colonies differs significantly from sample to sample. On an average we have observed 20 to 100 iPSC like colonies per well of a six well plate. 
5.3.
Aliquot 1 ml of mTeSR-1 medium supplemented with ROCK inhibitor in a 15 ml tube and 1.5 ml in a Matrigel coated well for each iPSC clone to be established. Place the plate in CO 2 incubator at 37°C, 5% CO 2 and atmospheric O 2 .
5.4.
Place the reprogramming plate on an inverted microscope kept in a laminar flow hood and pick 10-15 iPSC colonies that are morphologically similar to human ESCs ( Fig. 1 and Fig. 2A ) using a stretched glass Pasteur pipette or 200 μl pipette tip. Collect the picked colonies in the 15 ml tube(s) prepared in step 5.3. Alternatively, colonies may be live stained for TRA-1-81 or alkaline phosphatase for easy identification.
5.5.
After picking the desired number of colonies, gently pipette the medium containing iPSC colonies 2-3 times with a 1 ml pipette to achieve desired iPSC aggregate size.
5.6.
Plate the iPSC aggregates (0.5 ml in each well) in two wells of the six well plate prepared in step 5.3.
5.7.
Place the plate in a CO 2 incubator at 37°C, 5% CO 2 and atmospheric O 2 . Move the plate in several quick, short, back-and-forth and side-to-side motions to evenly distribute the cell aggregates. Do not disturb the plate for next 24 h.
5.8.
Change medium (mTeSR-1 without ROCK inhibitor) daily and visually assess cultures to monitor growth.
5.9.
On day 3 or 4 after plating, when iPSC colonies are easily distinguishable from differentiated cells. Remove the differentiated areas using a stretched glass Pasteur pipette or 200 μl pipette tip.
5.10.
On day 5 to 7 when iPSC colonies are ready for passaging, coat appropriate number of six well plate(s) with Matrigel hESC qualified matrix.
NOTE:
At this stage iPSCs can be passaged using either enzymatic (using Dispase enzyme) or non-enzymatic method. Here we describe a commonly used enzymatic method.
5.11
. Warm a 12 ml aliquot/six well plate of mTeSR-1 medium to room temperature (15°C-25°C) and add 10 μM ROCK inhibitor (Y-27632). TIP: Perform step 5.18 with a wide bore pipette to minimize the breakage of cell aggregates.
5.19.
Centrifuge the 15 ml tube containing cell aggregates at 90 × g for 5 min at room temperature.
5.20.
Remove supernatant and resuspend cell aggregates in 3 ml of mTeSR-1 medium supplemented with 10 μM ROCK inhibitor (Y-27632) prepared in step 5.11.
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5.21.
Plate the iPSC aggregates at a density of 1:6 to 1:10 depending upon the confluency of the iPSC wells, into the six well plate prepared in step 5.12.
5.22.
Place the plate in a CO 2 incubator at 37°C, 5% CO 2 and atmospheric O 2 . Move the plate in several quick, short, back-and-forth and side-to-side motions to evenly distribute iPSC aggregates. Do not disturb the plate for 24 h.
5.23.
5.24.
The cultures can be split every 4-7 d upon maturity of the iPSC colonies. The iPSCs should be passaged at least 3-5 times before characterization, functional validation, and experimental use. POL Scientific Protocol 7.17. Image stained iPSC colonies immediately or it can also be stored at 4°C in the dark for 1-2 d.
Functional validation of reprogrammed iPSCs
The functional competence of reprogrammed iPSC lines to differentiate into the cells of all the three germ layers (i.e., endoderm, mesoderm, and ectoderm) is assessed using commercially available hPSC functional identification kit or alternatively using the traditional teratoma formation assays. The procedure to perform monolayer differentiation into cells of all three germ layers using the hPSC functional identification kit is described below. 8. Culturing iPSCs for differentiation assays 8.1. Coat 2 wells in each of three 4 well plates with Cultrex PathClear BME supplied with the kit. 
8.11.
Place the plate in a CO 2 incubator at 37°C, 5% CO 2 and atmospheric O 2 . The next day cells should be approximately 50% confluent. If cells are not 50% confluent, replace medium with fresh mTeSR-1 medium and continue iPSC culture until 50% confluency is achieved.
8.12.
Label the plates as "endoderm", "mesoderm" and "ectoderm" and proceed for respective differentiation.
9. Endoderm differentiation 9.1. Prepare 2 ml of endoderm differentiation medium-I, as described in the kit's manual.
9.2.
Replace mTeSR-1 with endoderm differentiation medium-I (1 ml/well) in the plate labeled as "endoderm". Return the plate to CO 2 incubator.
9.3.
On day 2 about 16-24 h after replacing endoderm differentiation medium-I, prepare endoderm differentiation medium-II.
9.4.
Replace endoderm differentiation medium-I with endoderm differentiation medium-II. Return the plate to CO 2 incubator.
9.5.
Replace spent medium with fresh endoderm differentiation medium-II on day 3. 9.6. On day 4, cells are ready of immunocytochemistry analysis of endoderm markers. Proceed to immunocytochemistry analysis of germ layer markers.
Mesoderm differentiation
10.1. Prepare 2 ml of mesoderm differentiation medium, as described in the kit's manual.
10.2.
Replace mTeSR-1 with mesoderm differentiation medium (1 ml/well) in the plate labeled as "mesoderm". Return the plate to CO 2 incubator.
10.3.
After 12 to 16 h, replace spent medium with fresh mesoderm differentiation medium.
10.4.
Cells are ready for immunocytochemistry analysis of mesoderm markers within 24-36 h of differentiation. Proceed to immunocytochemistry analysis of germ layer markers.
Ectoderm differentiation
11.1. Prepare 2 ml of ectoderm differentiation medium, as described in the kit's manual.
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Protocol 11.2. Replace mTeSR-1 with ectoderm differentiation medium (1 ml/well) in the plate labeled as "ectoderm". Return the plate to CO 2 incubator.
11.3.
Repeat medium change with fresh ectoderm differentiation medium on day 2 and 3.
11.4.
On day 4 cells are ready of immunocytochemistry analysis of ectoderm markers. Proceed to immunocytochemistry analysis of germ layer markers.
Immunocytochemistry analysis of germ layer markers
12.1. Follow steps 7.3 to 7.5 to fix and permeabilize cells.
12.2.
Aspirate permeabilization buffer and add 0.5 ml of blocking buffer and incubate at room temperature for 1 h. 
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Genomic integrity of reprogrammed iPSCs
Prolonged culture and cellular manipulation involved in iPSC reprogramming may affect the genomic integrity of the reprogrammed iPSCs. Therefore, a test of genomic integrity is recommended. The most commonly used technique, by far, is the traditional karyotype analysis. Karyotyping is based on arresting the cells in metaphase stage of the cell division, followed by their staining, Giemsa staining (G-banding) is recommended. Alternatively, array-based molecular analyses of genomic integrity using commercially available microarray and kits may be employed.
ANTICIPATED RESULTS
The LCL reprogrammed iPSCs formed flat and compacted colonies and showed high nucleus-to-cytoplasm ratio, the typical morphology of human ESCs (Fig. 2A) . The immunocytochemistry and differential gene expression analysis showed that LCL reprogrammed iPSCs express pluripotency markers ( Fig. 2B and Fig. 3A-3C) . The LCL reprogrammed iPSCs also showed potential to differentiate into cells of all the three germ layers by in-vitro monolayer differentiation assays (Fig. 4) . Apart from the routine validation, we have successfully generated terminally differentiated cells of all the three germ layers such as neurons, cardiomyocytes and hepatocytes, using these LCL reprogrammed iPSCs (Fig. 5) . Overall, we achieved success in reprogramming cryopreserved LCLs of more than 200 San Antonio Family Heart Study participants in first attempt, except in two cases (~1.33%), the first attempt failed due to bacterial contaminations of the reprogramming culture. In these 200 successful reprogramming experiments more than 95% colonies out of 10 to 15 colonies screened per sample expressed pluripotency markers. One established iPSC clone per participant was tested for function competence and all tested iPSC clones successfully differentiated into cells of all the three germ layers.
LCLs show high expression of the B-cell activation markers (CD23, CD70, CD30, and CD39) and cellular adhesion molecules (CD11a, CD58, and CD54) [16] . These markers are usually absent or expressed at very low levels in resting B-cells, but their expression is significantly upregulated by EBV encoded nuclear antigens (EBNA2, EBNA3C) and latent membrane proteins (LMP1, LMP2A) when EBV infection is used to generate the LCLs [17] [18] [19] . The differential gene expression analysis of LCLs and their reprogrammed iPSCs (at 10 to 15 passage) shows significant downregulation of B-cell activation markers and cellular adhesion molecules in the reprogrammed iPSCs (Fig. 3D) , which supports previous findings that EBV transcriptional activity is inhibited in the reprogrammed iPSCs [12] [13] [14] . 
TROUBLESHOOTING
Possible problems and their troubleshooting solutions are listed in Table 1 . 
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